Nan Fung Trinity HK Ltd. Acquires Shares of 150,338 Merus N.V. $MRUS

Nan Fung Trinity HK Ltd. bought a new position in shares of Merus N.V. (NASDAQ:MRUS) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 150,338 shares of the biotechnology company’s stock, valued at approximately $7,908,000. Nan Fung Trinity HK Ltd. owned 0.22% of Merus as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of MRUS. CWM LLC boosted its holdings in Merus by 299.0% in the 2nd quarter. CWM LLC now owns 802 shares of the biotechnology company’s stock worth $42,000 after buying an additional 601 shares during the period. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Merus by 955.3% in the first quarter. Caitong International Asset Management Co. Ltd now owns 1,794 shares of the biotechnology company’s stock worth $76,000 after acquiring an additional 1,624 shares during the period. US Bancorp DE grew its position in shares of Merus by 324.1% in the first quarter. US Bancorp DE now owns 2,935 shares of the biotechnology company’s stock valued at $124,000 after purchasing an additional 2,243 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Merus by 15.7% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,674 shares of the biotechnology company’s stock valued at $141,000 after purchasing an additional 362 shares during the period. Finally, Avanza Fonder AB lifted its holdings in Merus by 14.1% during the 2nd quarter. Avanza Fonder AB now owns 3,136 shares of the biotechnology company’s stock worth $165,000 after purchasing an additional 387 shares in the last quarter. Institutional investors own 96.14% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on MRUS. Lifesci Capital reiterated a “market perform” rating and set a $97.00 price target on shares of Merus in a research report on Tuesday, September 30th. UBS Group downgraded shares of Merus from a “buy” rating to a “neutral” rating and raised their price target for the company from $72.00 to $97.00 in a report on Tuesday, September 30th. HC Wainwright cut shares of Merus from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $135.00 to $97.00 in a report on Monday, September 29th. Wall Street Zen lowered Merus from a “hold” rating to a “sell” rating in a research note on Sunday, July 20th. Finally, Canaccord Genuity Group lowered Merus from a “buy” rating to a “hold” rating and upped their target price for the stock from $67.00 to $97.00 in a research note on Monday, September 29th. Four equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $92.35.

Merus Stock Up 0.1%

NASDAQ MRUS opened at $95.48 on Wednesday. The stock’s 50-day simple moving average is $85.11 and its two-hundred day simple moving average is $66.28. Merus N.V. has a twelve month low of $33.19 and a twelve month high of $95.54. The company has a market capitalization of $7.24 billion, a price-to-earnings ratio of -18.02 and a beta of 1.26.

Merus Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.